Search Results - therapeuticarea+%3e+neurology

122 Results

Sort By:

Immunosuppressive Exosomes for Treating Autoimmune Diseases

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of immunosuppressive exosomes derived from IL-35 and IL-27 producing Bregs as a therapeutic treatment for autoimmune diseases. This technology includes the use of exosomes derived from Interleukin 35 (IL-35) and Interleukin 27 (IL-27) producing...

Published: 6/18/2026 | Updated: 6/16/2026 | Inventor(s): Minkyung Kang, Charles Egwuagu

Keywords(s):

Category(s): Application, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Carriers/Adjuvants, TherapeuticArea > Immunology, TherapeuticArea > Neurology, TherapeuticArea > Ophthalmology

Calcineurin Inhibitor-Antibody Conjugates for Targeted Treatment of Th17 Driven Inflammatory Diseases

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of calcineurin inhibitor-antibody conjugates aimed at treating Th17 driven inflammatory diseases. This technology includes calcineurin inhibitor-antibody conjugates designed for the targeted treatment of Th17 driven inflammatory diseases, such...

Published: 6/18/2026 | Updated: 6/16/2026 | Inventor(s): Andrew Dick, Lauren Schewitz Bowers, Robert Nussenblatt, Lai Wei, Igal Gery, Richard Lee

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Antibodies, TherapeuticArea > Immunology, TherapeuticArea > Ophthalmology, TherapeuticArea > Neurology

AI Based Workflow for Single Cell Analysis

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for single-cell RNA sequencing (scRNA-seq) analysis software that leverages existing large language models (LLM) to simplify and enhance data analysis by providing intelligent recommendations and interpretations. This technology includes SCassist, an innovative...

Published: 6/18/2026 | Updated: 6/16/2026 | Inventor(s): Rachel Caspi, Vijayaraj Nagarajan

Keywords(s):

Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma

This technology includes a first-in-class synthetic peptide, angubindin-1, designed to temporarily relax the blood-brain barrier (BBB)—the tightly sealed network of brain blood vessel cells that normally blocks most drugs—from the inside. By binding the tricellular tight-junction protein angulin-1/LSR, the peptide creates a reversible “molecular...

Published: 4/30/2026 | Updated: 4/30/2026 | Inventor(s): Sadhana Jackson

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration

Description of Technology: Axonal injury and subsequent neuronal death underpin the pathology of many neurological disorders from acute neural injuries (motor vehicle crashes, combat related injuries, traumatic brain injuries) to neurological diseases (multiple sclerosis, glaucoma). In the central nervous system (CNS), microglia help respond to CNS...

Published: 4/16/2026 | Updated: 4/16/2026 | Inventor(s): Wei Li, Jingxing Ou, Tantai Zhao

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Ear, Nose, & Throat, TherapeuticArea > Neurology, Collaboration Sought > Licensing

Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties

One of the most challenging hurdles in creating safe and effective new medicines for many diseases is finding drugs that are effective without causing off-target cardiac issues, such as cardiac arrythmias. In collaboration with NIDA, scientists at NCATS have developed a series of novel and highly specific dopamine D3 receptor agonists and antagonists...

Published: 11/14/2025 | Updated: 6/13/2025 | Inventor(s): Khalida Shamim, Wenwei Huang, Wei Zheng, Catherine Chen, Xiuli Huang, Xin Hu, Xin Xu, Pranav Shah, Elias Padilha, Philip Sanderson, Amy Newman

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, TherapeuticArea > Neurology, TherapeuticArea > Psychiatry/Mental Health

P2Y14 Receptor Antagonists for the Treatment of Inflammatory Diseases, Including Pulmonary and Renal Conditions and Chronic Pain

This technology includes the development of selective P2Y14R antagonists for the treatment of asthma, sterile inflammation of the kidney, diabetes, and neurodegeneration. The P2Y14 receptor (P2Y14R) is a target for the treatment of inflammatory diseases, including pulmonary and renal conditions. Selective P2Y14R antagonists have demonstrated efficacy...

Published: 6/11/2025 | Updated: 6/11/2025 | Inventor(s): Young-Hwan Jung, Zhiwei Wen, Kenneth Jacobson

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Endocrinology, TherapeuticArea > Metabolic Disease, TherapeuticArea > Neurology, TherapeuticArea > Pulmonology, TherapeuticArea > Respiratory

Fluorophthalimides as Anti-inflammatory Agents for Systemic and Neurodegenerative Disorder

Summary: The National Institute on Aging (NIA) seeks research co-development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic and neurodegenerative disorders. Description of Technology: Numerous systemic, as well as neurological disorders, have a hallmark inflammatory...

Published: 6/27/2025 | Updated: 5/2/2025 | Inventor(s): Nigel Greig, Weiming Luo, David Tweedie, Michael Scerba, Daniela Lecca, Shih Chang Hsueh

Keywords(s):

Category(s): TherapeuticArea > Neurology, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

4-Amino-2-(piperidin-3-yl)isoindoline-1,3-diones as Anti-inflammatory Agents for Systemic Degenerative and Neurodegenerative Disorders

Summary: The National Institute on Aging (NIA) seeks research co-development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic degenerative and neurodegenerative disorders. Description of Technology: The immunomodulatory imide drugs (IMiDs) thalidomide and its close...

Published: 6/27/2025 | Updated: 4/28/2025 | Inventor(s): Nigel Greig, Michael Scerba, David Tweedie

Keywords(s):

Category(s): TherapeuticArea > Geriatrics, TherapeuticArea > Neurology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Margaric Acid Decreases PIEZO2 Mediated Pain

Summary: The National Center for Complimentary and Integrative Health (NCCIH) seeks licensees and/or commercial partners to develop topical formulations of margaric acid to treat allodynia, neuropathy, and pain caused by chronic inflammation. Description of Technology: Some existing therapies for treatment of pain are administered systematically...

Published: 4/24/2026 | Updated: 3/10/2025 | Inventor(s): Alexander Chesler, Valeria Vasquez, Julio Cordero-Morales, Luis Romero

Keywords(s): ALLODYNIA, Chesler, Chronic Inflammation, fatty acid, Margaric Acid, migraine, National Center for Complimentary and Integrative Health, NCCIH, Neuropathy, Pain, PIEZO2, Vásquez

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Neurology, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Dermatology

1 2 3 4 5 6 7 8 9 10 ...